{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Can-Fite Biopharma Ltd"},"Symbol":{"label":"Symbol","value":"CANF"},"Address":{"label":"Address","value":"10 BAREKET STREET, KIRYAT MATALON,P.O. BOX 7537, PETAH-TIKVA, 4951778, Israel"},"Phone":{"label":"Phone","value":"+972 39241114"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Middle East"},"CompanyDescription":{"label":"Company Description","value":"Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH)."},"CompanyUrl":{"label":"Company Url","value":"http://www.canfite.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Michael Silverman","title":"Medical Director"},{"name":"Motti Farbstein","title":"Chief Executive, Financial & Operating Officer"},{"name":"Pnina Fishman","title":"Executive Chairman & Chief Scientific Officer"},{"name":"Zivit Harpaz","title":"Director-Regulatory & Clinical Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}